In The Media

WINNER - Citywire Best Specialist Equities 2017

14th November 2017


International Biotechnology Trust (IBT) triumphed in an eclectic category at the Citywire Investment Trust Awards, seeing off competition from property, technology and environmental funds to be crowned best Specialist Equities trust.


Our awards analysed trusts’ three-year risk-adjusted performance, and on that measure, IBT has performed impressively.


But that performance has been amplified for shareholders thanks to a steady rerating of the shares since the announcement last year that it would pay a 4% dividend.


Having traded at a discount of more than 20% three years ago, the shares have this month establish a small premium to net asset value.


In this short video, manager Ailsa Craig reflects on a strong year for the trust and discusses a possible catalyst for the next leg of the biotechnology sector’s rally.



Read Full Article 


2 top-performing investment trusts for growth and income

30th September 2017


For investors looking for growth and income from smaller companies, I reckon the Acorn Income Fund (LSE: AIF) deserves a closer look. The fund is a standout performer in the UK small-cap space, boasting some of the best figures across the board.


An investor who had bought shares in the investment trust five years ago would have earned a total return of 176%, a significantly better performance than the FTSE SmallCap (excluding investment companies) benchmark’s total return of 112%.


Read Full Article 


Dividends and biotech: a blockbuster combination?

14th August 2017


Anyone in doubt about the revitalising effect dividends can have on an investment trust’s share price need only look at International Biotechnology Trust (IBT).


Managers of the £223 million closed-end fund hope it may soon be able to issue shares for the first time in over a decade. That’s because of the apparently enthusiastic response to its proposal last September to start paying shareholders a 4% dividend from capital.


Read Full Article 


Trust in a third way for returns on biotech | The Times

23rd May 2017

Biotechnology companies tend to come in two types: those like Glaxosmithkline and Astrazeneca that offer investors a good and reliable income, and those that pay no dividends but are attractive prospects for that blockbuster drug that might, or might not, get through the regulatory process.

Read Full Article 




  • You are seeing this because you are accessing IBT’s website for the first time.
  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.
  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.
  • The material on this website is intended to be viewed only by persons resident in the EEA.
  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.
  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.
  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).